86604-77-5

Basic information

• Product Name: 4-Methoxy-3-Methyl-2-Pyridinemethanol
• Synonyms: 4-Methoxy-3-Methyl-2-Pyridinemethanol;2-Pyridinemethanol, 4-methoxy-3-methyl-;(4-Methoxy-3-methylpyridin-2-yl);2-HYDROXY METHYL-4-METHYL-3-METHYL PYRID INE
• CAS NO: 86604-77-5
• Molecular Formula: C₈H₁₁NO₂
• Molecular Weight: 153.17844
• Mol File: 86604-77-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 276.865°C at 760 mmHg
• Flash Point: 121.244°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.531
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.25±0.10(Predicted)
• CAS DataBase Reference: 4-Methoxy-3-Methyl-2-Pyridinemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-3-Methyl-2-Pyridinemethanol(86604-77-5)
• EPA Substance Registry System: 4-Methoxy-3-Methyl-2-Pyridinemethanol(86604-77-5)

Safety Data

• Hazardous Substances Data: 86604-77-5(Hazardous Substances Data)

Usage

General Description

4-Methoxy-3-Methyl-2-Pyridinemethanol is a chemical compound with the molecular formula C8H11NO2. It is a colorless to light yellow liquid that is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various other chemicals. 4-Methoxy-3-Methyl-2-Pyridinemethanol has a variety of applications, including as a solvent, a chemical intermediate, and a reagent in organic synthesis. Its unique structure and properties make it a valuable component in the manufacture of a wide range of products.

InChI:InChI=1/C8H11NO2/c1-6-7(5-10)9-4-3-8(6)11-2/h3-4,10H,5H2,1-2H3

Upstream product

• 22710-07-2 2,3-dimethylpyridine 1-oxide 
• 102625-96-7 4-methoxy-2,3-dimethylpyridine 1-oxide 
• 59886-90-7 4-chloro-2,3-dimethylpyridine-N-oxide 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 102625-98-9 2-acetoxymethyl-4-methoxy-3-methylpyridine 

Downstream Products

• 124473-12-7 2-chloromethyl-3-methyl-4-methoxypyridine 
• 86604-74-2 2-chloromethyl-4-methoxy-3-methylpyridine hydrochloride 
• 102804-77-3 2-[(RS)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole 
• 102804-82-0 2-[[(4-methoxy-3-methylpyridin-2-yl)methyl]mercapto]-1H-benzimidazole 
• 97966-86-4 2,2-difluoro-6-[(4-methoxy-3-methyl-2-pyridyl)methylsulfinyl]-5H-[1,3]-dioxolo-[4,5-f]benzimidazole 

Relevant articles and documents

HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION

Disclosed are: a compound which is stable in an acid, has an antibacterial effect against a bacterium Helicobacter pylori, can exert a satisfactory level of an antibacterial effect when used singly, does not affect an enteric bacterium, has an antibacterial effect against a bacterium resistant to an antibacterial agent, and has an inhibitory effect on gastric acid secretion; and a pharmaceutical composition comprising the compound. Specifically disclosed are: a compound represented by the general formula (I) or a salt thereof; and a pharmaceutical composition comprising the compound or the salt thereof: wherein R represents a linear alkyl group having 4 to 8 carbon atoms, preferably 5 to 7 carbon atoms.

Structure-activity relationship of 2-[[(2-Pyridyl)methyl]thio]-1H- benzimidazoles as anti Helicobacter pylori agents in vitro and evaluation of their in vivo efficacy

A relationship between the structure of 21 2-[[(2-pyridyl)methyl]thio]- 1H-benzimidazoles (6) and their anti Helicobacter pylori activity expressed as minimum bactericidal concentration (MBC) values is described. Observed MBCs ranged from 256 to 1 μg/mL. The structure - activity relationship (SAR) showed that larger and more lipophilic compounds, especially compounds with such substituents in the 4-position of the pyridyl moiety, generally had lower MBC values. Four new compounds 'that were predicted to be potent by the established SAR model were synthesized and tested. One such compound, i.e., 2-[[(4-[(cyclopropylmethyl)oxy]3-methyl-2-pyridyl)methyl]thio]-1H- benzimidazole (18), was tested for in vivo efficacy in a mouse Helicobacter felis model (125 μmol/kg bid given orally for 4 days, n = 4). Unfortunately, antibacterial activity could not be clearly demonstrated in this model. Instead a potent acid secretion inhibition was observed. This finding was attributed to the methylthio compound being oxidized to the corresponding methyl sulfinyl derivative, i.e., a proton pump inhibitor, in vivo. Although the antibacterial activity had the potential of decreasing H. felis cell counts in vivo the proton pump inhibitory effect became dominant and actually promoted H. felis cell growth. Hence, we conclude that the antibacterial utility of the 2-[[(2-pyridyl)methyl]thio]1H-benzimidazoles (6) as a compound class is compromised by their propensity to become proton pump inhibitors upon metabolic oxidation in vivo.

2--1H-thienoimidazoles. A Novel Class of Gastric H+/K+-ATPase Inhibitors

2-thienoimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase.The isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo.Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with additional electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thienoimidazole lead to highly active compounds with a favorable chemical stability.Various substitution patterns in the thienoimidazole moiety result in lower biological activity.The heptafluorobutyloxy derivative saviprazole (HOE 731, 5d) was selected for further development and is currently undergoing clinical evaluation.Comprehensive pharmacological studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.